Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Maher Albitar"'
Autor:
Maher Albitar, Hong Zhang, Andre Goy, Zijun Y. Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Fredrick B. Hagemeister, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Bing Xu, Ken H. Young
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 2, Pp 1-9 (2022)
Blood Cancer Journal, 12
Blood Cancer Journal, 12, 2
Albitar, M, Zhang, H, Goy, A, Xu-Monette, Z Y, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B & Young, K H 2022, ' Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms ', Blood Cancer Journal, vol. 12, no. 2, 25 . https://doi.org/10.1038/s41408-022-00617-5
Albitar, M, Zhang, H, Goy, A H, Xu-Monette, Z, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M, Parsons, B M, Van Krieken, J H J M, Piris, M A, Winter, J N, Li, Y, Xu, B & Young, K H 2021, ' Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms ', Blood, vol. 138, no. Suppl. 1, 2395 . https://doi.org/10.1182/blood-2021-148841
Blood Cancer Journal
Blood Cancer Journal, 12
Blood Cancer Journal, 12, 2
Albitar, M, Zhang, H, Goy, A, Xu-Monette, Z Y, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B & Young, K H 2022, ' Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms ', Blood Cancer Journal, vol. 12, no. 2, 25 . https://doi.org/10.1038/s41408-022-00617-5
Albitar, M, Zhang, H, Goy, A H, Xu-Monette, Z, Bhagat, G, Visco, C, Tzankov, A, Fang, X, Zhu, F, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M, Parsons, B M, Van Krieken, J H J M, Piris, M A, Winter, J N, Li, Y, Xu, B & Young, K H 2021, ' Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms ', Blood, vol. 138, no. Suppl. 1, 2395 . https://doi.org/10.1182/blood-2021-148841
Blood Cancer Journal
Introduction: Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology. However, these biological subgroups overlap clinically. While R-CHOP (rituximab, cyclophosphamide, doxor
Autor:
Virginia Burns, Sucha Sudarsanam, Cory Batenchuk, Vladislav Chizhevsky, Kim E. Zerba, Maher Albitar, Chelsea Jin
Publikováno v:
Journal of Clinical Pathology
AimsAt the time of analysis, two widely used, drug-specific, tumour-cell programmed death ligand 1 (PD-L1) assays were approved by the US Food and Drug Administration for anti-PD-1 therapies: the Dako PD-L1 immunohistochemistry (IHC) 28-8 pharmDx ass
Autor:
Alexandar Tzankov, Maurilio Ponzoni, Wayne Tam, Miguel A. Piris, Ken H. Young, Feng Zhu, Babak Shahbaba, Carlo Visco, Michael Boe Møller, Bing Xu, April Chiu, Hongwei Zhang, Eric D. Hsi, Karen Dybkær, Yong Li, Benjamin M. Parsons, Hong Zhang, Govind Bhagat, Ivan De Dios, Zijun Y. Xu-Monette, Youli Zu, Jooryung Huh, Hua You, Maher Albitar, Fredrick B. Hagemeister, Jane N. Winter, J. Han van Krieken, Andrés J.M. Ferreri
Publikováno v:
Blood Advances, 4, 28-3404
Blood Adv
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, De Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood advances, vol 4, iss 14
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, Han van Krieken, J, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, de Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood Advances, 4, 14, pp. 28-3404
Blood Adv
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, De Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood advances, vol 4, iss 14
Xu-Monette, Z Y, Zhang, H, Zhu, F, Tzankov, A, Bhagat, G, Visco, C, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, Han van Krieken, J, Piris, M A, Winter, J N, Hagemeister, F B, Shahbaba, B, de Dios, I, Zhang, H, Li, Y, Xu, B, Albitar, M & Young, K H 2020, ' A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL ', Blood advances, vol. 4, no. 14, pp. 3391-3404 . https://doi.org/10.1182/bloodadvances.2020001949
Blood Advances, 4, 14, pp. 28-3404
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cab6f4fba3f040d2a18798264b72db
http://hdl.handle.net/2066/222478
http://hdl.handle.net/2066/222478
Autor:
Babak Shahbaba, Kirk J. Wojno, Edward Uchio, Neal D. Shore, Wanlong Ma, Donald Moylan, Maher Albitar, Lars Lund, Søren Feddersen
Publikováno v:
Albitar, M, Ma, W, Lund, L, Shahbaba, B, Uchio, E, Feddersen, S, Moylan, D, Wojno, K & Shore, N 2018, ' Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer ', The Prostate, vol. 78, no. 4, pp. 294-299 . https://doi.org/10.1002/pros.23473
BACKGROUND: Distinguishing between low- and high-grade prostate cancers (PCa) is important, but biopsy may underestimate the actual grade of cancer. We have previously shown that urine/plasma-based prostate-specific biomarkers can predict high grade
Publikováno v:
Journal of Clinical Oncology. 38:e21535-e21535
e21535 Background: N TRK (NTRK1, NTRK2 or NTRK3) fusions are oncogenic drivers of various types of cancer and lead to activation of the PI3K/AKT pathway. Treatment of patients with NTRK fusion using TRK inhibitors, such as larotrectinib or entrectini
Autor:
Hong Zhang, Ivan De Dios, Spiraggelos Antzoulatos, Sanam Loghavi, Maher Albitar, Marina Konopleva, Koichi Takahashi, Wanlong Ma, Courtney D. DiNardo, Steven M. Kornblau, Hagop M. Kantarjian, Antonio Cavazos
Publikováno v:
Blood. 134:1314-1314
Introduction: The principle of precision cancer medicine is to customize therapy based on the genomic profiles of the cancer and the host constitution/response to the cancer. Since RNA expression is influence by many genetic mechanisms, RNA profiling
Publikováno v:
Molecular Diagnosis & Therapy
Introduction We compared mutations detected in EGFR, KRAS, and BRAF genes using next-generation sequencing (NGS) and confirmed by Sanger sequencing with mutations that could be detected by FDA-cleared testing kits. Methods Paraffin-embedded tissue fr
Publikováno v:
Genetic Testing and Molecular Biomarkers. 18:156-163
To avoid relying solely on serum prostate-specific antigen (sPSA) in screening for prostate cancer (PCa), we developed a scoring system for detecting PCa and the prediction of aggressiveness. We analyzed urine and plasma specimens from 121 patients w
Autor:
Maher Albitar, Sucha Sudarsanam, James K. McCloskey, Adam Albitar, Chirag S. Desai, Neil J. Shah, Jianhua Zhao, Jamie Koprivnikar, Catherine Lai
Publikováno v:
Blood. 132:1393-1393
Background: Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are heterogeneous groups of disorders with a spectrum of clinical presentations and outcomes. Prognosis depends on various factors including age, karyotype, performance stat
Autor:
Lawrence M. Weiss, Gregory Hess, Maher Albitar, Wayne Chen, Sally Agersborg, Christopher Mixon, Robert Gasparini, T. T. Nguyen, Forrest Blocker, Sramila Aithal, Shiping Jiang
Publikováno v:
Cancer Research. 78:4524-4524
PURPOSE While HER2 testing is well established in directing appropriate treatment for breast cancer, a small percentage of cases show equivocal results by IHC and FISH. Alternative probes may be used in equivocal cases. We present a single community-